

A Straightforward Approach toward Multifunctionalized Pyridazines via Imination/Electrocyclization

Alexander V. Komkov, Anna S. Komendantova, Leonid G. Menchikov, Elena I. Chernoburova, Yulia A. Volkova,* and Igor V. Zavarzin

N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky prosp., 119991 Moscow, Russia

Supporting Information



ABSTRACT: A facile synthesis of functionalized 3-carbamide pyridazines starting from readily available chlorovinyl aldehydes and oxamic acid thiohydrazides via cascade imination/electrocyclization is reported. In the presence of *p*-toluenesulfuric acid, various ketones have been efficiently incorporated into the pyridazine derivatives through a two-step sequence involving a Vilsmeier–Haack reaction and imination. The synthetic value of this method has been demonstrated by efficient synthesis of steroidal pyridazines.

D yridazines are an important structural subunit found in a variety of biologically active agents, including a number of natural products (e.g., Pyridazomycin¹ and Azamerone²) and major drugs (e.g., antihypertensive - hydralazine, dihydralzine, endralazine;³ antidepressants - pipofezine, minaprine).⁴ The prevalence of the pyridazine motif in medicinally relevant compounds,⁵ dyes,⁶ ligands for metal catalysts,⁷ and crystal engineering⁸ has inspired the development of many novel methods for their preparation.⁹ However, there are only limited protocols for assembling 3-carbonyl substituted pyridazine derivatives, important intermediates in organic synthesis.¹⁰ Traditional methods include diaza-Wittig reactions of 1,3diketones,¹¹ addition of diazo compounds to Morita–Baylis– Hillman carbonates,¹² [4 + 2] cycloaddition of substituted 1,2,3-triazines,¹³ cascade reactions of pyridiniumylides,¹⁴ and cycloaddition of 1,2,4,5-tetrazine with alkynes.¹⁵ Despite the impressive progress made in this area, it is still a great challenge to synthesize functionalized pyridazines from readily available and easily varied starting materials using a simple procedure. Known methods suffer from the requirements of a stringent anaerobic procedure, harsh conditions, and limited substrate scope.

On the other hand, electrocyclic processes are valued for their mild reaction conditions, excellent functional group tolerance, and ability to produce six-membered aromatic rings. There have been a number of reports over the past decade demonstrating the utility of azahexatrienes for synthesis of pyridines,¹⁶ 1,2-dihydropyridines,¹⁷ and pyrimidines.¹⁸ In particular, transformations of 1-ethoxy-4-azahexatrines **1** into pyridines 2^{16b} and cyclization of 1-dimethyamine-2,4-azahexatrienes 3 to give pyrimidines 4^{18} should be mentioned. To the best of our knowledge, diazahexatrienes in the synthesis of pyridazines are unknown to date.

Reasonably, we proposed a 2,3-diazahexatrienyl system bearing a carbonyl group along with a good leaving group can be effective for 3-carboxy pyridazine construction (Scheme 1). Initial sourcing of 2,3-azahexatrienyl synthons possessing a carboxy moiety clued us to hydrazones of oxamic acid thiohydrazides.¹⁹ Distinctive thione—thiol tautomerism together with the SH good leaving group character made them highly promising substrates for transformations. The presence of a chlorine atom in their structure could favor the aromatization step, whereby we intensely examined β -chlorohydrazones 5 as precursors for pyridazines 6. Note that hydrazones 5 are readily available from ketones by the Vilsmeier—Haack reaction and subsequent imination with oxamic acid thiohydrazides.

We initiated our investigation on the model reaction of chlorovinyl aldehyde **8a** derived from 2-hexanone (7a) with hydrazide **9a** in the presence of TsOH (10 mol %) to optimize various reaction parameters. Full data concerning the optimization of temperature (rt \rightarrow 120 °C), solvent (toluene, CHCl₃, CH₃CN, EtOH, 2-methoxyethanol), and amounts of the reagents are presented in the Supporting Information. It was found the principal result was the formation of pyridazines **10a** as the major product in all cases (Scheme 2).

Received: June 12, 2015

Scheme 1. Azahexatrienes in the Synthesis of Carboxy Substituted Azaheterocycles





Heterocyclization proceeded smoothly even at room temperature, and complete conversion of the starting material was achieved within 18 h with a good yield of pyridazine 10a. Solvent effect was not observed; reactions in toluene and 2methoxyethanol gave comparable yields of product 10a (80% and 83%, respectively). The best result was obtained by performing the reaction in refluxing 2-methoxyethanol for 5 min to afford compound 10a in 84% yield (Scheme 3).

With optimal reaction conditions in hand, we studied the use of various ketones 7b–l as well as different hydrazides 9b-d to synthesize a variety of 3-carbomide-4,5-disubstituted pyridazines derivatives (Scheme 3). Three general procedures differing in temperature (A, 120 °C; B, 80 °C; C, rt) and solvent were applied in accordance with the intermediate chlorovinyl aldehyde thermal stability.

It was found that this method is quite general since both symmetrical and asymmetrical linear aliphatic ketones reacted smoothly providing diverse pyridazines 10a-d in excellent yields. Cyclic aliphatic ketones, such as cycloheptanone, -hexanone, and -pentanone, produced the corresponding pyridazines 10f-j in slightly lower yields (49–81%) that can



"Reaction conditions: (A) aldehyde 8 (0.22 mmol), hydrazide 9 (0.22 mmol), and TsOH (10 mol %) in 2-methoxyethanol (2.5 mL) at 120 °C for 5–10 min; (B): aldehyde 8 (0.22 mmol), hydrazide 9 (0.22 mmol), and TsOH (10 mol %) in ethanol (2.5 mL) at refux for 5 min–2 h; (C) aldehyde 8 (0.22 mmol), hydrazide 9 (0.22 mmol), and TsOH (10 mol %) in ethanol (2.5 mL) at rt overnight. ^bIsolated yield. 'Yield calculated with respect to intermediate chlorovinyl aldehyde purity.

Organic Letters

be attributed to decomposition side processes and low solubility of products.

In addition, a 4-tetrahydropyranone 7k, as well as a 4piperidone 7l, was tolerated under these reaction conditions. Substituted 7,8-dihydro-5*H*-pyrano[3,4-*d*]pyridazine 10k and 5,6,7,8-tetrahydropyrido[3,4-*d*]pyridazine 10l were obtained in 57% and 66% yields. The reaction could also be performed with aromatic ketones, namely, propiophenone 7e, producing the corresponding product 10e in reasonable yield.

Diverse hydrazydes 9a-d bearing MeO, Me, CF₃, Cl groups in *ortho-*, *meta-*, and *para-*positions were well tolerated under the reaction conditions to give the corresponding pyridazines 10m,n,p-q in moderate to good yields. In addition to arylamides, benzyl derivative can also be employed to form the corresponding 10r in 84% yield.

The structures of pyridazines 10 were confirmed by single crystal X-ray analysis of the representative compound 10b (Figure 1). The structures of 10j,k,m–o were supported by 2D NMR ($^{13}C^{-1}H$ HMBC and HSQC) techniques.



Figure 1. General view of X in representation of atoms by thermal ellipsoids (p = 50%) for compound 10b.

Having established a framework of the method with relatively simple molecules, we extended this method to complex natural products. In this respect, we turned to steroids, one of the largest and most diverse class of natural products.²⁰ Heterosteroids bearing annulated azaheterocycles are known to exhibit a wide range of biological activities, e.g., antiinflammatory,²¹ antimicrobial,²² antiproliferation,²³ and antitumor properties.²⁴ We first examined 3β -hydroxyandrost-5-en-17-one **11** and estrone **13** under standard conditions (Scheme 4).

It was found that both compounds 11 and 13 were readily transformed into the corresponding D-ring annulated steroidal pyridazines 12 and 14 (82% and 79%, respectively) upon subsequent treatment with Vilsmeier–Haack reagent and oxamic acid thiohydrazides 9a,e in the presence of catalytic amounts of TsOH (Scheme 4). A-Ring annulated steroidal pyridazine 16 was obtained similarly from dihydrotestosterone 15 in 73% yield.

The possible mechanism for the formation of pyridazines 10 by the reaction of chlorovinyl aldehyde 8 with oxamic acid thiohydrazides 9 is shown in Scheme 5 illustrating an example of product 10b. Imination of the aldehyde 8b with 9a under acid catalysis produces 2,3-azahexatirene intermediate 17. The E/Z-geometric isomers and thiol—thione tautomers equilibrate under the reaction conditions, and the Z-17-thiol isomer undergoes 6π -electrocyclization to afford an intermediate dihydropyridine 18. Rapid hydrochloric acid and molecular sulfur elimination deliver the observed pyridazine product 10b. The last step was confirmed experimentally since sulfur was isolated in equimolar amounts in all reactions.

The mechanistic rationalization of the observed cyclization remains, at least in part, speculative. The simultaneous presence of a nucleophilic SH-center and electrophilic chlorovinyl



Scheme 4. Synthesis of Steroidal Pyridazines







moiety in hydrazone 17b makes possible nucleophilic cyclizations to occur. However, computational studies on activation barriers and heat of the presented disrotatory electrocyclization reaction were found to be without a rival

Organic Letters

low $\Delta H_r = 6-12$ kcal/mol, $E_A^{\ddagger} = 2.4-8$ kcal/mol [B3LYP/6-311+G(d,p) and semiempirical PM6].²⁵

In summary, a novel effective approach to the synthesis of pyridazines by the two-stage procedure from ketones was described. The approach employs simple reactions comprising (1) Vilsmeier–Haack reaction of enolizable ketone leading to chlorovinyl aldehydes and (2) imination of the former with oxamic acid thiohydrazides and cascade electrocyclization/ aromatization of the resulting 2,3-diazatriene affording highly substituted pyridazines in moderate to excellent isolated yields (32–89%). Starting materials are readily available, and functional group tolerance is quite good. The ease of 2,3-diazahexatriene system construction and the broad availability of reagents imply that an extensive range of substituents can be selectively incorporated in the pyridazine ring. The full potential of this methodology and an exploration of a greater variety of substituents must await additional studies.

ASSOCIATED CONTENT

S Supporting Information

Detailed experimental procedures, spectral data for all products, and the X-ray data for **10b** (CIF). The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.5b01718.

AUTHOR INFORMATION

Corresponding Author

*E-mail: yavolkova@gmail.com.

Notes

The authors declare no competing financial interest.

REFERENCES

(1) (a) Bockholt, H.; Beale, J. M.; Rohr, J. Angew. Chem., Int. Ed. Engl. 1994, 33, 1648. (b) Grote, R.; Chen, Y.; Zeeck, A. J.; Chen, Z.; Zähner, H.; Mischnick-Lübbecke, P.; König, W. A. J. Antibiot. 1988, 41, 595.

(2) Cho, J. Y.; Kwon, H. C.; Williams, P. G.; Jensen, P. R.; Fenical, W. Org. Lett. 2006, 8, 2471.

(3) Sinha, B. K.; Mason, R. P. J. Drug Metab. Toxicol. 2014, 5, 168.
(4) Wermuth, C. G.; Schlewer, G.; Bourguignon, J. J.; Maghioros, G.; Bouchet, M.-J.; Moire, C.; Kan, J.-P.; Worms, P.; Biziere, K. J. Med. Chem. 1989, 32, 528.

(5) (a) Wermuth, C. G. MedChemComm 2011, 2, 935. (b) Asif, M. Curr. Med. Chem. 2012, 19, 2984.

(6) Do, J.; Huh, J.; Kim, E. Langmuir 2009, 25, 9405.

(7) (a) Slater, J. W.; Lydon, D. P.; Alcock, N. W.; Rourke, J. P. *Organometallics* **2001**, *20*, 4418. (b) Guo, T.; Dechert, S.; Meyer, S.; Meyer, F. *Organometallics* **2012**, *31*, 8537.

(8) (a) Wang, D.-Y.; Qin, L.-L.; Hou, X.-L.; Ye, H.-Y. *Chin. Chem. Lett.* **2015**, *26*, 145. (b) Varughese, S.; Draper, S. M. *Cryst. Growth Des.* **2010**, *10*, 2571.

(9) (a) Gulevich, A. V.; Dudnik, A. S.; Chernyak, N.; Gevorgyan, V. *Chem. Rev.* **2013**, *113*, 3084. (b) Eftekhari-Sis, B.; Zirak, V.; Akbari, A. *Chem. Rev.* **2013**, *113*, 2958. (c) Majumdar, P.; Pati, A.; Patra, M.; Behera, R.; Behera, A. K. *Chem. Rev.* **2014**, *114*, 2942.

(10) (a) Silva, P. J. J. Org. Chem. 2012, 77, 4653. (b) Filák, L.; Rokob, T. A.; Vaskó, G. Á.; Egyed, O.; Gömöry, A.; Riedl, Z.; Hajós, G. J. Org. Chem. 2008, 73, 3900.

(11) Bel Abed, H.; Mammoliti, O.; Bande, O.; Van Lommen, G.; Herdewijn, P. *J. Org. Chem.* **2013**, *78*, 7845.

(12) Mao, H.; Lin, A.; Tang, Z.; Hu, H.; Zhu, C.; Cheng, Y. Chem. -Eur. J. 2014, 20, 2454.

(13) Anderson, E. D.; Duerfeldt, A. S.; Zhu, K.; Glinkerman, C. M.; Boger, D. L. Org. Lett. **2014**, *16*, 5084. (14) Tomilov, Yu. V.; Platonov, D. N.; Dorokhov, D. V.; Zhalnina, A. A. *Russ. Chem. Bull.* **2008**, *57*, 1252.

(15) Moisan, L.; Odermatt, S.; Gombosuren, N.; Carella, A.; Rebek, J. Eur. J. Org. Chem. **2008**, 2008, 1673.

(16) (a) Trost, B. M.; Gutierrez, A. C. Org. Lett. 2007, 9, 1473.
(b) Beccalli, E. M.; Clerici, F.; Gelmi, M. L. Tetrahedron 2000, 56, 4817. (c) Kleine, T.; Frohlich, R.; Wibbeling, B.; Wurthwein, E. J. Org. Chem. 2011, 76, 4591.

(17) (a) Trost, B. M.; Biannic, B. Org. Lett. 2015, 17, 1433.
(b) Colby, D. A.; Bergman, R. G.; Ellman, J. A. J. Am. Chem. Soc. 2008, 130, 3645.

(18) Landreau, C.; Deniaud, D.; Reliquet, A.; Reliquet, F.; Meslin, J. J. Heterocycl. Chem. 2001, 38, 93.

(19) Milevsky, B. G.; Soloveva, N. P.; Chibisova, T. A.; Yarovenko, V. N.; Zayakin, E. S.; Chernyshev, V. V.; Krayushkin, M. M.; Traven, V. F. *Russ. Chem. Bull.* **2012**, *61*, 2311.

(20) Lednicer, D. Steroid Chemistry at a Glance; John Wiley & Sons Ltd.: 2011; p 144.

(21) Amr, A. E.; Abdulla, M. M. Bioorg. Med. Chem. 2006, 14, 4341.
(22) Gogoi, S.; Shekarrao, K.; Duarah, A.; Bora, T. C.; Gogoi, S.; Boruah, R. C. Steroids 2012, 77, 1438.

(23) Zhang, B.; Song, L.; Li, Y.; Li, Y.; Guo, Y.; Zhang, E.; Liu, H. Steroids 2014, 80, 92.

(24) (a) Zhang, B.; Zhang, E.; Pang, L.; Song, L.; Li, Y.; Yu, B.; Liu, H. *Steroids* **2013**, 78, 1200. (b) Shekarrao, K.; Kaishap, P. P.; Gogoi, S.; Boruah, R. C. *RSC Adv.* **2014**, *4*, 14013.

(25) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Keith, T.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian 09, Revision D.01; Gaussian, Inc.: Wallingford, CT, 2013.